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Abstract
We aimed to develop a cost-effective and robust method to predict drug resistance in individual 
patients. Representative tissue fragments were obtained from tumors removed from female 
patients, aged 24-74 years old. The tumor tissue was taken by a histopathology’s or a surgeon 
under sterile conditions. Cells obtained by enzymatic dissociation from tumor after surgery, were 
cultured as a monolayer for 6 days. Paclitaxel, doxorubicin, carboplatin and endoxan alone or 
in combination were added at the beginning of culture and after 6 days, Alamar blue test was 
used for showing action on cell proliferation why caspase- 3 activity assays for verifying action 
on apoptosis. Inhibitory action on cell proliferation was noted in 2 of 12 patients tumor treated 
with both single and combined drugs. Using caspase-3 assay we showed that 50% of tumor cells 
was resistant to single chemotherapeutic drugs and 40% for combined. In 2 of 12 tumors, which 
did not reacted on single drugs, positive synergistic action on cell proliferation was observed 
in combination of D + E and C + E. This pilot study suggests: 1) monolayer culture of tumor 
cells, derived from individual patients, before chemotherapy could provide a suitable model for 
studying resistance for drugs; 2) caspase-3 activity is cheap and useful methods; 3) Alamar blue 
test should be taken into consideration for measuring cell proliferation.
Keywords: Ovarian cancer; Monolayer cell culture; Chemotherapeutic drugs; Casapase-3 
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Introduction
Ovarian cancer is the most lethal gynecologic 
malignancy in the developed world (1), and there 
are still some debates about whether it is better 
to use chemotherapy before or after surgery. 
Currently, the preferred treatment regimen for 
ovarian cancer is combination chemotherapy; 
usually a platinum based drug, such as cisplatin 
or carboplatin, coupled with paclitaxel.
However, advanced ovarian cancer typically 
becomes chemo-refractory within approximately 
2 years, and second-line treatment options do not 
provide a significant survival advantage (2). It 
has been showed previously, similar response 
rate between 10-40% of several agents that have 
been used, including retreatment with paclitaxel 
and carboplatin (3-6). Therefore, it is important 
to identify agents or drug combinations that are 
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Experimental
Material and methods
Reagents 
Hams F-10 medium, collagenase type H, 
antibiotic-antimycotic solution (100 ×), fetal 
bovine serum (FBS, heat-inactivated) and trypan 
blue were obtained from Sigma Chemical Co. 
(St. Louis, USA). Phosphate-buffered saline 
(PBS) was purchased from the Laboratory of 
Sera and Vaccines (Lublin, Poland). Paclitaxel, 
doxorubicin, carboplatin and endoxan were 
obtained from the Oncological Surgery 
Department of the National Cancer Institute, 
Cracow Branch, and Poland.
Tumors samples 
Representative tissue fragments were 
obtained from tumors removed from female 
patients, aged 24-74 years old, who were treated 
in the Department of Gynecological Oncology, 
Cracow Center of Oncology. The characteristics 
of the tumors studied are depicted in the Table 
1, classified according to Tavassoli et al. (12). 
Twelve, well-defined primary malignant tumors 
were selected for this study. These included six 
serous adenocarcinoma, three endometrioid 
adenocarcinoma, one serous adenoma of 
borderline malignancy, one serous cystadenoma 
of borderline malignancy, and one surface 
papillary adenocarcinoma.
Tumor tissue was taken by a histopathology’s 
or surgeon under sterile conditions, and 
transported to the laboratory in PBS with 
antibiotics (100U/mL penicillin and 100ng/
mL streptomycin) at 4°C. Ovarian tumor tissue 
was cut into small pieces and placed in Petri 
dishes containing PBS. Cells were obtained by 
enzymatic dissociation, primarily using 0.75mg/
mL collagenase (Sigma Cat No. C-8051), 
repeated three times for 15 min at 37°C. Cells 
were then assessed for viability by trypan blue 
exclusion. Approximately 20,000–30,000 cells/
well were added to each well of a 96-well plate 
with 200µL/well 10% (FBS) medium. Plates 
were then incubated at 37°C in 5% CO2 for 24h 
to allow the cells to attach. Cell culture medium 
was then replaced with Hams F-10 containing 
5% FBS and the following drugs: paclitaxel 
(13.8 µM), doxorubicin (2.5 µM), carboplatin 
active in recurrent disease and can be used as 
salvage chemotherapy for epithelial ovarian 
cancer (EOC). The two most pressing problems 
in the management of ovarian cancer are the 
lack of adequate screening strategies and the 
chemoresistancy of recurrent disease. In part, the 
deficiency in diagnostic tools is due to the lack 
of markers for the detection of preneoplastic or 
early neoplastic changes in the ovarian surface 
epithelial cells. The wide spectrum toxic side 
effects of cytotoxic treatments, as well as 
drug resistance, are important limitations for 
the management of ovarian cancer and thus, 
methods to rapidly assess the effectiveness of 
treatments for individual patients are needed 
(7). 
Studies in cell lines do not always correlate 
well with results from tumor tissue, which 
may consist largely of non-neoplastic cells that 
support and modify the biology of neoplastic 
cells (8). Therefore, it is necessary to identify 
robust and rapid methods to assess the action 
of chemotherapeutic drugs on biopsy material 
or tissue taken during surgery. Ideally, the 
method should have the ability to determine 
individual patient responses to each drug. 
Extreme drug resistance (EDR) assays have 
been used to identify chemotherapy regimens 
that are least likely to be of clinical benefit in 
the treatment of EOC (9). EDR assay results do 
not independently predict or alter the outcomes 
of patients with EOC who are treated with the 
current standards of primary cytoreductive 
surgery followed by platinum and taxane 
combination chemotherapy. Extreme drug 
resistance assay results do not influence survival 
in women with epithelial ovarian cancer 
(10). EDR is methodologically similar to the 
thymidine incorporation assay, using metabolic 
incorporation of titrated thymidine to measure 
cell viability. 
The ability of a cancer cell to respond to 
a chemotherapeutic agent is believed to be 
due, in part, to its apoptotic capacity (11). In 
the present study we decided to determine the 
effect of single or combined chemotherapeutic 
drugs on proliferation using Alamar Blue test 
and caspase-3 activity as a key biomarker for 
apoptosis in ovarian cancer cells obtained from 
patients after surgery. 
Caspase-3 activity, as a key biomarker for apoptosis in ovarian tumor cell culture
1155
carboplatin; 5) doxorubicin plus endoxan; or 6) 
carboplatin plus endoxan. Drug doses were based 
on those of Nicolantonio et al. (13) and doses 
used during chemotherapy. The experiment was 
terminated after 6 days. After cell culture, cell 
proliferation was measured using an Alamar 
Blue assay. Cells were stored at -20° C prior to 
estimation of caspase-3 activity.
Measurement of cell proliferation using 
Alamar Blue 
Alamar Blue assay (Bio Source International, 
USA) is designed to measure quantitatively the 
proliferation of various human and animals cell 
lines based on detection of metabolic activity. 
The active ingredient is resazurin (IUPAC name: 
7-hydroxy-10-oxidophenoxazin-10-ium-3-one), 
also known as diazo-resorcinol, azoresorcin, 
resazoin, resazurine, which is water-soluble, 
stable in culture medium, is non-toxic and 
permeable through cell 50 years to assess cell 
viability and cytotoxicity in a range of biological 
and environmental systems and in a number 
of cell types including bacteria, yeast, fungi, 
protozoa and cultured mammalian and piscine 
cells. It offers several advantages over other 
metabolic indicators and other cytotoxicity 
assays (14, 15). The REDOX indicator produces 
a clear, stable distinct change which is easy to 
Table 1. Characteristics of ovarian cancers studied. *classified 
according to Tavassoli FA, Devilee P (Eds), WHO Classification 
of Tumours. Pathology and Genetics of Tumours of the Breast 
and Female Genital Organs, IARC Press Lyon 2003.
Table 2. Percent inhibition (-) or stimulation (+) of cell proliferation by chemotherapuetic agents. Cells were treated with paclitaxel (P), 
carboplatin (C), doxorubicin (D), endoxan (E), paclitaxel plus doxorubicin (P + D), paclitaxel plus carboplatin (P + C), paclitaxel plus 
endoxan (P + E), doxorubicin plus carboplatin (D + C), doxorubicin plus endoxan (D + E), or carboplatin plus endoxan (C + E). 
(13.4µM), or endoxan (19µM), either alone or 
in the following combinations: 1) paclitaxel plus 
doxorubicin; 2) paclitaxel plus carboplatin; 3) 
paclitaxel plus endoxan; 4) doxorubicin plus 
Case no Age of patient Histological type of tumor*
1 64 Serous adenocarcinoma G.3
2 74 Serous adenocarcinoma G.3
3 67 Serous adenocarcinoma G.3
4 24 Serous adenoma of borderline malignancy
5 56 Serous adenocarcinoma G.3
6 72 Serous adenocarcinoma
7 47 Surface papillary adenocarcinoma
8 30 Serous cystadenoma of borderline malignancy
9 43 Endometrioid adenocarcinoma
10 63 Endometrioid adenocarcinoma G.2
11 53 Endometrioid adenocarcinoma G2
12 48 Serous adenocarcinoma
Chemotherapeutic drugs
Patient P C D E P+D P+C P+E D+C D+E C+E
P1 -30 -50 -56 -54 -25 -25 -30 -50 -50 -50
P2 +40 0 0 0 +40 +30 +40 0 0 0
P3 +190 0 0 0 +110 +102 +85 10 0 0
P4 +20 0 0 0 +40 +20 +25 +10 +10 +10
P5 +40 0 0 0 +70 +50 +50 +10 +10 0
P6 +35 0 0 0 +90 +70 +80 +100 0 +60
P7 +30 +30 +10 0 +40 +20 +40 +50 0 +10
P8 +70 +10 0 0 +90 +70 +60 +10 +10 0
P9 +60 0 0 0 +70 +60 +30 0 0 +10
P10 -25 -74 -77 0 -55 -50 -27 -40 -40 -20
P11 +70 +10 +10 +10 +106 +90 +90 +20 +20 +10
P12 +102 0 0 0 +90 +100 +90 0 +20 +10
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interpret. After 6 days of culture, Alamar Blue 
was aseptically added to culture wells in an 
amount equal to 10% of the incubation volume, 
and after a 5 h-incubation the absorbance of the 
medium was measured at 570 nm and 600 nm 
wavelengths using a fluorescence microplate 
reader (BioTek Instruments, VT, USA).
Measurement of apoptosis by caspase-3 
activity 
The caspase-3 colorimetric assay is based on 
the hydrolysis of the peptide substrate acetyl-
Asp-Glu-Val-Asp p- nitroanilide (Ac-DEVD-
pNa) by caspases-3, resulting in the release 
p-nitroaniline (pNA) moiety. The concentration 
of the pNA released from the substrate is 
calculated from the absorbance values at 405 
nm. The comparison of the absorbance of pNA 
from an apoptotic sample with an uninduced 
control allows determination of the fold increase 
in caspase-3 activity. After replacing media 
with caspase assay buffer (50 mM HEPES, 
pH 7.4, 100 mM NaCl, 0.1% CHAPS, 1 mM 
EDTA, 10% glycerol and 10 mM DTT), 
cell lysates were incubated with a caspase-3 
colorimetric substrate, acetyl-Asp-Glu-Val-Asp-
p-nitroanilide-7-amino-4-methylcoumarin (Ac-
DEVD-AMC conjugation); Sigma). Reaction 
mixtures were incubated at 37°C for 15 min to 
1h, and the absorbance was measured at 405nm 
using an ELISA microplate reader (BioTek 
Instruments). Caspase 3, which is an effector 
caspase, is the most studied of mammalian 
caspases. Caspase 3 plays a central role in 
mediating nuclear apoptosis including chromatin 
condensation and DNA fragmentation as well as 
cell blebbing. Caspase 3 activity is tissue, cell 
type, or death stimulus specific. 
Statistical analysis 
Each treatment was repeated three times (n = 
3) in quadruplicates, and the average of the values 
was used for statistical calculations. Statistical 
analysis was performed using Stastistica 6.0 
(StatSoft Inc., OK, USA). Data were analyzed 
by one-way analysis of variance (ANOVA) 
followed by the Tukey honestly significant 
difference (HSD) multiple range test.
Results and Discussion
In the presented data we used monolayer 
cell cultures obtained from individual patients. 
Cells were exposed for 6 days to individual 
or combined chemotherapeutic drugs. Figure 
1 shows a representative six days monolayer 
culture in control and drug treated cells. 
It has been showed that 80% of the tumor cells 
Table 3. Percent stimulation (+) of apoptosis by chemotherapuetic agents. Cells were treated with paclitaxel (P), carboplatin (C), 
doxorubicin (D), endoxan (E), paclitaxel plus doxorubicin (P + D), paclitaxel plus carboplatin (P + C), paclitaxel plus endoxan (P + E), 
doxorubicin plus carboplatin (D + C), doxorubicin plus endoxan (D + E), or carboplatin plus endoxan (C + E). 
Chemoteraupetic drugs
Patient P C D E P+D P+C P+E D+C D+E C+E
P1 0 0 0 0 0 0 0 0 0 0
P2 0 0 0 0 0 0 0 0 0 0
P3 0 0 0 0 0 0 0 0 0 0
P4 0 43 + +30 +50 0 0 +35 0 +50 +60
P5 0 0 0 0 0 0 0 0 0 0
P6 0 0 0 0 0 0 0 0 0 0
P7 +80 +98 +80 +80 0 +141 +165 0 +200 +260
P8 +80 +60 +80 +85 +45 +90 +108 0 +220 +280
P9 0 0 0 0 0 +80 0 +70 +95 +70
P10 +80 0 +45 0 0 0 +60 0 0 0
P11 +195 +102 +40 +130 +190 +160 +160 0 +70 +90
P12 0 0 0 0 0 0 0 0 0 0
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stimulated cell proliferation (Figure 2), and in 
10 of the 12 cultures, all of the combinations 
containing paclitaxel stimulated cell proliferation 
(Figure 3). According to a new study recently 
published in the peer-reviewed journal Nature, 
chemotherapy not only promotes the growth and 
spread of cancer cells by damaging the healthy 
tissue that surrounds tumors, but it also causes 
were resistant to chemotherapeutic drugs. We 
observed inhibition of cell proliferation in two 
of the 12 tumor cultures treated with paclitaxel, 
carboplatin or doxorubicin using Alamar Blue 
test, and only one of the 12 cultures treated with 
endoxan (Figure 1). Four of the 12 cultures did 
not respond to the single or combined drugs. 
In six of the 12 tumor cell cultures, paclitaxel 
Figure 1. Phase contrast photomicrographs of ovarian tumor cells derived from patient 1, and cultured for 6 days in (a) control media or 
(b) media containing paclitaxel plus carboplatin.
Figure 2. Effect of individual chemotherapeutic drugs on tumor cell proliferation. Cells derived from 12 patients (P1–12) were treated 
with paclitaxel (13.8µM), doxorubicin (2.5µM), carboplatin (13.4µM), or endoxan (19µM) for 6 days. Cell proliferation was measured 
using an Alamar Blue assay. *p < 0.05, **p < 0.01, statistically significant inhibition or stimulation of cell proliferation.
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Figure 3. Effect of combined chemotherapeutic drugs on tumor cell proliferation. Cells were 
treated with paclitaxel plus doxorubicin (P + D), paclitaxel plus carboplatin (P + C), paclitaxel 
plus endoxan (P + E), doxorubicin plus carboplatin (D + C), doxorubicin plus endoxan (D + E), 
or carboplatin plus endoxan (C + E) for 6 days. Cell proliferation was measured using an Alamar 
Blue assay. *p < 0.05, statistically significant inhibition of cell proliferation; #p < 0.05, 
statistically significant stimulation of cell proliferation. 
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Figure 4. Effect of individual chemotherapeutic drugs on tumor cell apoptosis. Cells were treated with paclitaxel (13.8µM), doxorubicin 
(2.5µM), carboplatin (13.4µM) or endoxan (19µM) for 6 days. Apoptosis was measured using a caspase-3 assay. *p < 0.05, **p < 0.01, 
statistically significant stimulation of apoptosis; #p < 0.05, statistically significant inhibition of apoptosis.
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Figure 3. Effect of combined chemotherapeutic drugs on tumor cell proliferation. Cells were treated with paclitaxel plus 
doxorubicin (P + D), paclitaxel plus carboplatin (P + C), paclitaxel plus endoxan (P + E), doxorubicin plus carboplatin (D 
+ C), doxorubicin plus endoxan (D + E), or carboplatin plus endoxan (C + E) for 6 days. Cell proliferation was measured 
using an Alamar Blue assay. *p < 0.05, statistically significant inhibition of cell proliferation; #p < 0.05, statistically 
significant stimulation of cell proliferation.
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Apoptosis is programmed cell death that involves the controlled dismantling of 
intracellular components while avoiding inflammation and damage to surrounding cells. 
Apoptosis is a mode of programmed cell death that is coordinated by members of the caspases 
family of cysteine proteases. The caspase-3 plays a central role in the execution-phase of cell 
apoptosis. Several attempts have been made within the last decade to develop molecules capable 
of directly activating caspase-3 for use in cancer therapy. A particular target suggested for 
intervention has been the “safety catch” sequence present in inactive procaspase-3 (17). Using 
caspase-3 activity assays we noted that six of the 12 (50%) tumor cell cultures were resistant to 
single chemotherapeutic drugs. Caspase-3 activity in three of the 12 tumor cell culture was 
stimulated by all four drugs tested, whereas two of the 12 cell culture were stimulated by two or 
three of the drugs (Figure 4). Combination treatments had no effect on five of the 12 cell lines 
(40%). Two tumor cell cultures that did not respond to single drug treatments responded to two of 
the four combinations, and five of the 12 tumor cell cultures which were resistant to single drugs 
were also resistant to combination treatments (Figure 5). 
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with paclitaxel (13.8µM), doxorubicin (2.5µM), carboplatin (13.4µM) or endoxan (19µM) for 6 
days. Apoptosis was measured using a caspase-3 assay. *p < 0.05, **p < 0.01, statistically 
significant stimulation of apoptosis; #p < 0.05, statistically significant inhibition of apoptosis. 
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Figure 5. Effect of combined chemotherapeutic drugs on tumor cell apoptosis. Cells were treated with paclitaxel plus doxorubicin (P + 
D), paclitaxel plus carboplatin (P + C), paclitaxel plus endoxan (P + E), doxorubicin plus carboplatin (D + C), doxorubicin plus endoxan 
(D + E), or carboplatin plus endoxan (C + E) for 6 days. Apoptosis was measured using a caspase-3 assay. *p < 0.05, **p < 0.01, ***p 
< 0.001, statistically significant stimulation of caspase-3 activity. 
cancer cells to develop full-on resistance to the 
popular treatment, morphing them into “super” 
cancer cells (16) which would explain the our 
findings in the case of some patients.
Apoptosis is programmed cell death 
that involves the controlled dismantling of 
intracellular components while avoiding 
inflammation and damage to surrounding cells. 
Apoptosis is a mode of programmed cell death 
that is coordinated by members of the caspases 
family of cysteine proteases. The caspase-3 
plays a central role in the execution-phase of cell 
apoptosis. Several attempts have been made 
within the last decade to develop molecules 
capable of directly activating caspase-3 for use 
in cancer therapy. A particular target suggested 
for intervention has been the “safety catch” 
sequence present in inactive procaspase-3 (17). 
Using caspase-3 activity assays we noted that six 
of the 12 (50%) tumor cell cultures were resistant 
to single chemotherapeutic drugs. Caspase-3 
activity in three of the 12 tumor cell culture was 
stimulated by all four drugs tested, whereas two 
of the 12 cell culture were stimulated by two 
or three of the drugs (Figure 4). Combination 
treatments had no effect on five of the 12 cell 
lines (40%). Two tumor cell cultures that did 
not respond to single drug treatments responded 
to two of the four combinations, and five of the 
12 tumor cell cultures which were resistant to 
single drugs were also resistant to combination 
treatments (Figure 5).
The results presented are in agreement with 
previously published data. Chemotherapeutic 
drug resistance is a common feature of 
ovarian cancer and is a major problem given 
that the majority of EOCs are in an advanced 
stage when a diagnosis is made (18). The 
standard therapy for women with advanced 
EOC is paclitaxel, or similar, cisplatin-based 
combinations (19). Paclitaxel combined with 
cisplatin or carboplatin is a favored regimen 
for treating epithelial cell ovarian cancer. It 
produces complete disease regression in about 
one quarter of patients with Stage III disease, 
with two thirds of patients having a meaningful 
therapeutic response. 
In clinical trials in 1989, paclitaxel was 
reported to produce partial or complete responses 
in 30% of patients with advanced ovarian cancer 
(19). Recently, the Gynecologic Oncology Group 
reported that the incorporation of paclitaxel into 
first-line therapy for ovarian cancer improved 
the duration of progression-free survival, and 
overall survival (20, 21). Di Nicolantonio et al. 
(13) have shown development of such resistance 
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to combination chemotherapy in tumor-derived 
cells from matched biopsies collected from breast 
cancer patients before and after administration 
of doxorubicin-containing chemotherapy. This 
study suggests that up-regulation of resistance 
genes or down-regulation of target genes may 
occur rapidly in human solid tumors within 
days of treatment commencing, and that 
similar changes are present in pre- and post-
chemotherapy biopsy material. The molecular 
processes used by each tumor appear to be linked 
to the drug used, but there is also heterogeneity 
between individual tumors, even those with the 
same histological type, in terms of the response 
pattern and magnitude to the same drugs. 
Adaptation to chemotherapy may explain why 
prediction of resistance mechanisms is difficult 
on the basis of tumor type alone or individual 
markers, and suggests that more complex 
predictive methods are required to improve the 
response rates to chemotherapy. 
Our data are also in agreement with recent 
published data by Pitakkarnkul et al. (4), 
which showed that the overall response rate 
to paclitaxel treatment for 41 patients was 
41.5%, but was only 12.5% for patients with 
refractory or platinum-resistant cancer, and 
was 48.5% for patients with platinum-sensitive 
disease. Stable disease was demonstrated in 
17% of patients while progressive disease was 
apparent in 41.5%. The same study also showed 
that neutropenia, neuropathy and alopecia are 
common side effects. Sharma et al. (3) evaluated 
clinical responses following ATP-tumor chemo 
sensitivity assay-directed salvage chemotherapy 
in 44 patients with advanced ovarian cancer. Of 
the 44 patients, 18 were resistant to platinum-
based treatments and 31 were resistant to 
cisplatin (3). A recent paper by van der Burg 
et al. (5) demonstrated that weekly paclitaxel/
carboplatin followed by 3-weekly cycles is 
highly effective against platinum-resistant 
EOC. After six 3-weekly cycles, 51% of the 
platinum-resistant patients had a response, and 
77% received clinical benefits with relief of 
symptoms. Furthermore, Tan et al. (6) recently 
investigated the efficacy of paclitaxel in 26 
patients with BRCA1- and BRCA2-mutated 
ovarian cancers, producing a response rate to 
paclitaxel monotherapy of 46%. 
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Conclusion
Activation of the caspase-3 pathway is a 
hallmark of apoptosis and can be used in cellular 
assays to quantify activators and inhibitors of 
the “death cascade. Our data suggest that simple, 
monolayer cultures of tumor cells and caspase-3 
assays as a key biomarker for apoptosis are a 
relatively cheap and fast method taken before 
chemotherapy. This representative apoptosis 
assay can be used in an automated way and is 
amenable to development of high-throughput 
applications. However, the effective response 
of the patients, from whom cell cultures were 
derived, to front line chemotherapy and if the in-
vitro assay will really predictive of response.
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